{"id":790,"date":"2017-02-26T19:12:39","date_gmt":"2017-02-26T19:12:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?page_id=790"},"modified":"2026-03-17T11:43:56","modified_gmt":"2026-03-17T15:43:56","slug":"lonafarnib-pre-clinical-drug-supply-program","status":"publish","type":"page","link":"https:\/\/www.progeriaresearch.org\/it\/lonafarnib-pre-clinical-drug-supply-program\/","title":{"rendered":"Programma di fornitura di farmaci preclinici Lonafarnib"},"content":{"rendered":"

Italiano: [et_pb_section fb_built=\u201d1\u2033 larghezza completa=\u201don\u201d disabilitato_on=\u201doff|off|off\u201d versione_builder=\u201d4.16\u2033 larghezza_bordo_bottom=\u201d55px\u201d colore_bordo_bottom=\u201d#29327a\u201d bloccato=\u201doff\u201d info_colori_global=\u201d{}\u201d][et_pb_fullwidth_header versione_builder=\u201d4.18.1\u2033 carattere_titolo=\u201d||||||||\u201d title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201don|desktop\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dbackground-position: center 18% !important;\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

Preclinico di Lonafarnib<\/h1>\n

Programma di fornitura di farmaci<\/h1>\n

 <\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dhandprint-bg\u201d _builder_version=\u201d4.16\u2033 background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png\u201d parallax=\u201don\u201d parallax_method=\u201doff\u201d larghezza_interna=\u201d100%\u201d larghezza_interna_massima=\u201d100%\u201d imbottitura_personalizzata=\u201d0|0px|54px|0px|falso|falso\u201d z_index_tablet=\u201d500\u2033 larghezza_interna_massima=\u201d10px\u201d colore_interna_massima=\u201d#8fd2ed\u201d usa_larghezza_personalizzata=\u201don\u201d unit\u00e0_di_larghezza=\u201doff\u201d percentuale_larghezza_personalizzata=\u201d100%\u201d info_colori_globali=\u201d{}\u201d][et_pb_column tipo=\u201d1_4\u2033 versione_builder=\u201d4.16\u2033 imbottitura_personalizzata=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_sidebar area=\u201det_pb_widget_area_14\u2033 disabled_on=\u201don|on|off\u201d module_class=\u201dsubpage-sidebars\u201d _builder_version=\u201d4.16\u2033 animation_style=\u201dfade\u201d z_index_tablet=\u201d500\u2033 border_width_right=\u201d5px\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d]
\nItaliano: [\/et_pb_sidebar][\/et_pb_column][et_pb_column type=\u201d3_4\u2033 specialty_columns=\u201d3\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_row_inner _builder_version=\u201d4.16\u2033 background_color=\u201d#00b2e2\u2033 custom_margin=\u201d41px||\u201d custom_margin_tablet=\u201d0px||\u201d custom_margin_phone=\u201d\u201d custom_margin_last_edited=\u201don|phone\u201d custom_padding=\u201d39.4375px|20px|0|20px|false|true\u201d animation_style=\u201dslide\u201d animation_direction=\u201dtop\u201d animation_intensity_slide=\u201d25%\u201d box_shadow_style=\u201dpreset1\u2033 box_shadow_blur=\u201d38px\u201d box_shadow_spread=\u201d-12px\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dLonafarnib disponibile per la ricerca\u201d _builder_version=\u201d4.18.1\u2033 header_2_line_height=\u201d1.2em\u201d background_layout=\u201ddark\u201d custom_margin=\u201d||35px\u201d custom_padding=\u201d|50px||\u201d custom_padding_tablet=\u201d|50px||50px||true\u201d custom_padding_phone=\u201d\u201d custom_padding_last_edited=\u201don|desktop\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d\u201d header_font_size_last_edited=\u201don|desktop\u201d header_2_font_size_tablet=\u201d25px\u201d header_2_font_size_phone=\u201d\u201d header_2_font_size_last_edited=\u201don|tablet\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d19px\u201d header_4_font_size_last_edited=\u201don|phone\u201d header_4_line_height_tablet=\u201d\u201d header_4_line_height_phone=\u201d1.2em\u201d header_4_line_height_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 informazioni_globali_colori=\u201d{}\u201d]<\/p>\n

Lonafarnib disponibile per la ricerca<\/strong><\/h2>\n

Italiano: [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201don|phone\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201dtop\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201don|on|\u201d admin_label=\u201dTesto + Immagine\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

\"\"PRF rende disponibile alla comunit\u00e0 di ricerca l'inibitore della farnesiltransferasi, lonafarnib. Il nostro obiettivo \u00e8 supportare studi preclinici per indagare ulteriormente gli effetti del lonafarnib sulla Progeria.<\/p>\n

La missione incrollabile di PRF \u00e8 trovare trattamenti migliori e una cura per i bambini affetti da Progeria. \u00c8 stato dimostrato che il lonafarnib apporta benefici ad alcuni aspetti della malattia clinicamente (Gordon et al, PNAS, 2012) e aumenta la durata della vita (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018), ma non \u00e8 curativo. Man mano che vengono identificati nuovi composti con il potenziale per migliorare l'HGPS, prevediamo la necessit\u00e0 di testare questi composti in combinazione con il lonafarnib in vitro e nei modelli animali.<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261\u00d7300.jpg\u201d align=\u201dcenter\u201d align_tablet=\u201dcenter\u201d align_phone=\u201d\u201d align_last_edited=\u201don|desktop\u201d disabled_on=\u201d||on\u201d admin_label=\u201dImmagine (solo per dispositivi mobili)\u201d _builder_version=\u201d4.16\u2033 z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text disabled_on=\u201doff|off|on\u201d admin_label=\u201dTesto (solo per dispositivi mobili)\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 global_colors_info=\u201d{}\u201d]<\/p>\n

PRF sta rendendo disponibile alla comunit\u00e0 di ricerca l'inibitore della farnesiltransferasi lonafarnib. Il nostro obiettivo \u00e8 supportare studi preclinici per indagare ulteriormente gli effetti del lonafarnib sulla Progeria.<\/p>\n

La missione incrollabile di PRF \u00e8 trovare trattamenti migliori e una cura per i bambini affetti da Progeria. \u00c8 stato dimostrato che il lonafarnib apporta benefici ad alcuni aspetti della malattia dal punto di vista clinico (Gordon et al, PNAS, 2012) e che influenza l'aumento della durata di vita stimata (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018), ma non \u00e8 curativo. Man mano che vengono identificati nuovi composti con il potenziale per migliorare l'HGPS, prevediamo la necessit\u00e0 di testare questi composti in combinazione con il lonafarnib in vitro e nei modelli animali.<\/p>\n

Italiano: [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=\u201don|phone\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d|35px|0|0px|false|false\u201d custom_padding_tablet=\u201d|35px||35px||true\u201d custom_padding_phone=\u201d\u201d animation_direction=\u201dtop\u201d global_colors_info=\u201d{}\u201d][et_pb_column_inner saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text disabled_on=\u201don|on|\u201d admin_label=\u201dNote tecniche\u201d _builder_version=\u201d4.18.1\u2033 header_4_line_height=\u201d1.2em\u201d header_4_font_size_tablet=\u201d\u201d header_4_font_size_phone=\u201d23px\u201d header_4_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 box_shadow_horizontal_tablet=\u201d0px\u201d box_shadow_vertical_tablet=\u201d0px\u201d box_shadow_blur_tablet=\u201d40px\u201d box_shadow_spread_tablet=\u201d0px\u201d global_colors_info=\u201d{}\u201d]<\/p>\n

Note tecniche<\/strong><\/h4>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-solubility.pdf” button_text=”Solubility PDF” admin_label=”Solubility PDF Button” _builder_version=”4.16″ background_layout=”dark” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-administration-to-mice.pdf” button_text=”Administration PDF” admin_label=”Admin pdf button” _builder_version=”4.16″ background_layout=”dark” custom_margin=”20px|||” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner column_structure=”1_2,1_2″ custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_margin=”39px||” custom_padding=”0|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_direction=”right” global_colors_info=”{}”][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Ordering Information” _builder_version=”4.27.5″ header_4_line_height=”1.2em” hover_enabled=”0″ header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Informazioni per l'ordinazione<\/b><\/h4>\n

Il materiale \u00e8 fornito gratuitamente. Il destinatario paga tutte le spese di spedizione. Per ricevere lonafarnib, compila una domanda e un accordo di trasferimento del materiale e invialo a e-mail: wnorris@brownhealth.org<\/a><\/p>\n

Domanda e accordo<\/a><\/p>\n

Accordo di trasferimento di materiale per istituzioni non governative**<\/a><\/p>\n

**<\/strong>\u00a0La PRF ha una politica di\u00a0nessuna modifica al nostro MTA<\/strong>.<\/p>\n

Italiano: [\/et_pb_text][\/et_pb_column_inner][et_pb_column_inner type=\u201d1_2\u2033 saved_specialty_column_type=\u201d3_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|20px|30px|20px\u201d custom_padding_tablet=\u201d|0px||0px\u201d custom_padding_phone=\u201d||30px\u201d custom_padding_last_edited=\u201don|desktop\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/FTI-graph.jpg\u201d align=\u201dcenter\u201d align_tablet=\u201dcenter\u201d align_phone=\u201d\u201d align_last_edited="on|desktop" _builder_version="4.16" animation_style="slide" animation_direction="right" animation_intensity_slide="25%" global_colors_info="{}"]
\n[\/et_pb_image][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_padding=”25px|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_style=”slide” animation_direction=”right” animation_intensity_slide=”25%” border_width_top=”10px” border_color_top=”#8fd2ed” border_width_bottom=”10px” border_color_bottom=”#29327a” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Contacts for Questions and Assistance:” _builder_version=”4.27.2″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

Contatti per domande e assistenza:<\/strong><\/h4>\n

Ricercatore principale: Leslie B. Gordon, MD, PhD;\u00a0lgordon@progeriaresearch.org<\/a><\/p>\n

Banca di cellule e tessuti PRF: Wendy Norris; e-mail: wnorris@brownhealth.org<\/a><\/p>\n

Per le istituzioni del governo federale degli Stati Uniti o per domande, contattare Wendy Norris, coordinatrice dello studio di ricerca, all'indirizzo e-mail: wnorris@brownhealth.org<\/a>\u00a0o 401 274-1122 x 48063<\/span>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 module_class=\u201dfooter\u201d _builder_version=\u201d4.21.0\u2033 background_color=\u201d#29327a\u201d custom_margin=\u201d-2px|||||\u201d custom_padding=\u201d0|0px|0|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d12px\u201d border_color_top=\u201d#00b2e2\u2033 global_module=\u201d133\u2033 locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row column_structure=\u201d1_4,1_4,1_2\u2033 make_equal=\u201don\u201d module_class=\u201d et_pb_row_fullwidth\u201d _builder_version=\u201d4.16\u2033 width=\u201d89%\u201d width_tablet=\u201d80%\u201d width_phone=\u201d\u201d width_last_edited=\u201don|desktop\u201d max_width=\u201d89%\u201d max_width_tablet=\u201d80%\u201d max_width_phone=\u201d\u201d max_width_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 make_fullwidth=\u201don\u201d width_unit=\u201doff\u201d custom_width_percent=\u201d100%\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d button_text=\u201dIscriviti ora\u201d admin_label=\u201dIscriviti per gli aggiornamenti\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.27.4\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d link_option_url=\u201dhttps:\/\/lp.constantcontactpages.com\/sl\/88gWWwz\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201don|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201don\u201d button_bg_color__hover=\u201d#8fd2ed\u201d button_border_color__hover_enabled=\u201don\u201d]<\/p>\n

Iscrizione<\/h2>\n

per il nostro<\/h2>\n

Aggiornamenti!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_cta button_url=\u201dhttps:\/\/progeriaresearch.donorsupport.co\/-\/XZHJVWZR\u201d button_text=\u201dFai una donazione ora\u201d admin_label=\u201dInsieme troveremo la cura!\u201d module_class=\u201dsign-btn\u201d _builder_version=\u201d4.16\u2033 header_font_size=\u201d25px\u201d background_color=\u201d#29327a\u201d animation_style=\u201dslide\u201d animation_direction=\u201dleft\u201d animation_intensity_slide=\u201d25%\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d30px\u201d header_font_size_last_edited=\u201don|desktop\u201d body_font_size_tablet=\u201d\u201d body_font_size_phone=\u201d\u201d body_font_size_last_edited=\u201don|desktop\u201d z_index_tablet=\u201d500\u2033 border_radii=\u201don|25px|25px|25px|25px\u201d global_colors_info=\u201d{}\u201d button_bg_color__hover_enabled=\u201don\u201d colore_bg_pulsante__hover=\u201d#8fd2ed\u201d colore_bordo_pulsante__hover_abilitato=\u201don\u201d]<\/p>\n

Insieme, noi<\/h2>\n

VOLERE<\/em><\/h2>\n

trova la cura!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2026\/03\/2026-footer-image-copy.png” title_text=”2026 footer image copy” _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”35px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

Italiano: [et_pb_section fb_built=\u201d1\u2033 larghezza completa=\u201don\u201d disabilitato_on=\u201doff|off|off\u201d versione_builder=\u201d4.16\u2033 larghezza_bordo_bottom=\u201d55px\u201d colore_bordo_bottom=\u201d#29327a\u201d bloccato=\u201doff\u201d info_colori_global=\u201d{}\u201d][et_pb_fullwidth_header versione_builder=\u201d4.18.1\u2033 carattere_titolo=\u201d||||||||\u201d Italiano: title_font_size=\u201d55\u2033 background_color=\u201d#29327a\u201d background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg\u201d background_position=\u201dcenter_left\u201d custom_padding=\u201d9vw||9vw||true\u201d custom_padding_tablet=\u201d\u201d custom_padding_phone=\u201d|56px||\u201d custom_padding_last_edited=\u201don|desktop\u201d title_font_size_tablet=\u201d45px\u201d title_font_size_phone=\u201d40px\u201d title_font_size_last_edited=\u201don|phone\u201d z_index_tablet=\u201d500\u2033 custom_css_main_element=\u201dbackground-position: center 18% !important;\u201d global_colors_info=\u201d{}\u201d] Programma di fornitura di farmaci preclinici di Lonafarnib [\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 use_custom_gutter=\u201don\u201d gutter_width=\u201d1\u2033 specialty=\u201don\u201d padding_left_1=\u201d35px\u201d padding_left_2=\u201d35px\u201d padding_2_tablet=\u201d|||0px\u201d padding_2_phone=\u201d|||0px\u201d padding_2_last_edited=\u201don|desktop\u201d module_class_1=\u201dsidebar-secondary-nav\u201d module_class=\u201dhandprint-bg\u201d _builder_version=\u201d4.16\u2033 Italiano: background_image=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png\u201d parallax=\u201don\u201d parallax_method=\u201doff\u201d inner_width=\u201d100%\u201d inner_max_width=\u201d100%\u201d custom_padding=\u201d0|0px|54px|0px|false|false\u201d z_index_tablet=\u201d500\u2033 border_width_top=\u201d10px\u201d [\u2026]<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\t\t\t\t[vc_row][vc_column][vc_custom_heading text=\"Lonafarnib Pre-clinical Drug Supply Program\" font_container=\"tag:h1|text_align:center\" use_theme_fonts=\"yes\"][vc_column_text]July 2015: Lonafarnib Now Available for Research<\/strong>\r\n\r\nPRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\r\n\r\nIt is PRF's steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012)\u00a0as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014)\u00a0but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.\r\n\r\nMany thanks to the pharmaceutical company Merck for making this program possible.<\/strong>\r\n\r\nOrdering Information<\/b>\r\n\r\nThe material is supplied at no cost.\u00a0 Recipient pays for all shipping charges.\r\n\r\nTo receive lonafarnib, please fill out an application and material transfer agreement, and submit to joan_brazier@brown.edu<\/a>\r\n\r\n<\/a>Application and Agreement<\/a>\r\n\r\nMaterial Transfer Agreement for Non-government Institutions<\/a>**\r\n\r\n**<\/strong> PRF has a policy of no changes to our MTA<\/strong>.\r\n\r\n<\/strong>\r\n\r\nContacts for Questions and Assistance:<\/strong>\r\n\r\nPrincipal Investigator: Leslie B. Gordon, MD, PhD; lgordon@progeriaresearch.org<\/a>\r\n\r\nResearch Study Coordinator: Joan Brazier; joan_brazier@brown.edu<\/a>\r\n\r\nFor U.S. Federal Government Institutions or questions, please contact Joan Brazier, Research Study Coordinator, at joan_brazier@brown.edu<\/a> or 401-863-9628.[\/vc_column_text][\/vc_column][\/vc_row]\t\t","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-790","page","type-page","status-publish","hentry"],"yoast_head":"\nLonafarnib drug supply | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/it\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonafarnib drug supply | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/it\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T15:43:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"497\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\",\"name\":\"Lonafarnib drug supply | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"datePublished\":\"2017-02-26T19:12:39+00:00\",\"dateModified\":\"2026-03-17T15:43:56+00:00\",\"description\":\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonafarnib Pre-clinical Drug Supply Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonafarnib drug supply | The Progeria Research Foundation","description":"PRF sta rendendo disponibile alla comunit\u00e0 di ricerca l'inibitore della farnesiltransferasi lonafarnib. Il nostro obiettivo \u00e8 supportare studi preclinici per indagare ulteriormente gli effetti del lonafarnib sulla Progeria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/it\/lonafarnib-pre-clinical-drug-supply-program\/","og_locale":"it_IT","og_type":"article","og_title":"Lonafarnib drug supply | The Progeria Research Foundation","og_description":"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/it\/lonafarnib-pre-clinical-drug-supply-program\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_modified_time":"2026-03-17T15:43:56+00:00","og_image":[{"width":497,"height":572,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Progeria","twitter_misc":{"Est. reading time":"4 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","url":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","name":"Lonafarnib drug supply | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","datePublished":"2017-02-26T19:12:39+00:00","dateModified":"2026-03-17T15:43:56+00:00","description":"PRF sta rendendo disponibile alla comunit\u00e0 di ricerca l'inibitore della farnesiltransferasi lonafarnib. Il nostro obiettivo \u00e8 supportare studi preclinici per indagare ulteriormente gli effetti del lonafarnib sulla Progeria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Lonafarnib Pre-clinical Drug Supply Program"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Fondazione per la ricerca sulla progeria","description":"Per i bambini \u2665 Per la cura","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Fondazione per la ricerca sulla progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/pages\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":2,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/pages\/790\/revisions"}],"predecessor-version":[{"id":21465,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/pages\/790\/revisions\/21465"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/media?parent=790"}],"curies":[{"name":"parola chiave","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}